QQQ   352.93 (+1.18%)
AAPL   179.86 (+1.15%)
MSFT   325.58 (+0.68%)
META   265.00 (+0.53%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.49 (+3.97%)
NVDA   387.20 (+3.32%)
NIO   7.76 (+0.00%)
BABA   86.43 (+1.35%)
AMD   121.19 (+2.85%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.30 (-2.62%)
CGC   0.71 (-2.19%)
GE   106.58 (+0.47%)
DIS   92.44 (-0.09%)
AMC   4.73 (+0.00%)
PFE   39.06 (+0.44%)
PYPL   64.39 (+0.55%)
NFLX   405.95 (+1.55%)
QQQ   352.93 (+1.18%)
AAPL   179.86 (+1.15%)
MSFT   325.58 (+0.68%)
META   265.00 (+0.53%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.49 (+3.97%)
NVDA   387.20 (+3.32%)
NIO   7.76 (+0.00%)
BABA   86.43 (+1.35%)
AMD   121.19 (+2.85%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.30 (-2.62%)
CGC   0.71 (-2.19%)
GE   106.58 (+0.47%)
DIS   92.44 (-0.09%)
AMC   4.73 (+0.00%)
PFE   39.06 (+0.44%)
PYPL   64.39 (+0.55%)
NFLX   405.95 (+1.55%)
QQQ   352.93 (+1.18%)
AAPL   179.86 (+1.15%)
MSFT   325.58 (+0.68%)
META   265.00 (+0.53%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.49 (+3.97%)
NVDA   387.20 (+3.32%)
NIO   7.76 (+0.00%)
BABA   86.43 (+1.35%)
AMD   121.19 (+2.85%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.30 (-2.62%)
CGC   0.71 (-2.19%)
GE   106.58 (+0.47%)
DIS   92.44 (-0.09%)
AMC   4.73 (+0.00%)
PFE   39.06 (+0.44%)
PYPL   64.39 (+0.55%)
NFLX   405.95 (+1.55%)
QQQ   352.93 (+1.18%)
AAPL   179.86 (+1.15%)
MSFT   325.58 (+0.68%)
META   265.00 (+0.53%)
GOOGL   122.05 (-0.37%)
AMZN   123.96 (+2.25%)
TSLA   233.49 (+3.97%)
NVDA   387.20 (+3.32%)
NIO   7.76 (+0.00%)
BABA   86.43 (+1.35%)
AMD   121.19 (+2.85%)
T   16.04 (-0.37%)
F   13.57 (-0.15%)
MU   65.30 (-2.62%)
CGC   0.71 (-2.19%)
GE   106.58 (+0.47%)
DIS   92.44 (-0.09%)
AMC   4.73 (+0.00%)
PFE   39.06 (+0.44%)
PYPL   64.39 (+0.55%)
NFLX   405.95 (+1.55%)
NASDAQ:GERN

Geron (GERN) Stock Forecast, Price & News

$3.69
+0.13 (+3.65%)
(As of 03:04 PM ET)
Compare
Today's Range
$3.55
$3.71
50-Day Range
$1.97
$3.62
52-Week Range
$1.18
$3.84
Volume
2.98 million shs
Average Volume
7.80 million shs
Market Capitalization
$1.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Geron MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
35.1% Upside
$5.00 Price Target
Short Interest
Healthy
4.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-3.19
Upright™ Environmental Score
News Sentiment
0.03mentions of Geron in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$191,800 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.36) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

611th out of 981 stocks

Pharmaceutical Preparations Industry

296th out of 481 stocks


GERN stock logo

About Geron (NASDAQ:GERN) Stock

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Needham Reaffirms Their Buy Rating on Geron (GERN)
Goldman Sachs Reaffirms Their Hold Rating on Geron (GERN)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Geron (GERN) Receives a Buy from Robert W. Baird
Wedbush Sticks to Their Buy Rating for Geron (GERN)
Company News for May 12, 2023
Q1 2023 Geron Corp Earnings Call
Geron Corporation Q1 Loss beats estimates
Geron (GERN) Q1 2023 Earnings Call Transcript
Geron: Q1 Earnings Snapshot
See More Headlines

GERN Price History

GERN Company Calendar

Last Earnings
5/11/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+35.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-141,900,000.00
Net Margins
-30,349.19%
Pretax Margin
-30,349.19%

Debt

Sales & Book Value

Annual Sales
$600,000.00
Book Value
$0.20 per share

Miscellaneous

Free Float
492,995,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
0.90

Key Executives

  • John A. Scarlett
    Chairman, President & Chief Executive Officer
  • Andrew J. Grethlein
    Chief Operating Officer & Executive Vice President
  • Olivia K. Bloom
    Chief Financial Officer, Treasurer & Executive VP
  • Faye Feller
    Chief Medical Officer & Executive Vice President
  • Stephen N. Rosenfield
    Secretary, Chief Legal Officer & Executive VP













GERN Stock - Frequently Asked Questions

Should I buy or sell Geron stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price forecast for 2023?

5 Wall Street research analysts have issued 12 month price objectives for Geron's shares. Their GERN share price forecasts range from $3.00 to $7.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2023?

Geron's stock was trading at $2.42 at the start of the year. Since then, GERN shares have increased by 52.5% and is now trading at $3.69.
View the best growth stocks for 2023 here
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.14 million. Geron had a negative net margin of 30,349.19% and a negative trailing twelve-month return on equity of 91.38%. During the same period last year, the business posted ($0.09) EPS.

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.19%), State Street Corp (5.02%), Wellington Management Group LLP (2.16%), FMR LLC (1.60%), Geode Capital Management LLC (1.59%) and Fairmount Funds Management LLC (1.40%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $3.69.

How much money does Geron make?

Geron (NASDAQ:GERN) has a market capitalization of $1.88 billion and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-141,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.

This page (NASDAQ:GERN) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -